Amyloid-beta (Aβ) oligomers are thought to trigger Alzheimer's disease pathophysiology.
Cellular prion protein (PrP C ) selectively binds oligomeric Aβ and can mediate Alzheimer's …

Reducing the risk of dementia can halt the worldwide increase of affected people. The
multifactorial and heterogeneous nature of late‐onset dementia, including Alzheimer's disease (…

A pathological hallmark of Alzheimer’s disease is an accumulation of insoluble plaque
containing the amyloid-β peptide of 40–42 amino acid residues 1 . Prefibrillar, soluble oligomers …

Soluble amyloid-β oligomers (Aβo) trigger Alzheimer's disease (AD) pathophysiology and
bind with high affinity to cellular prion protein (PrP C ). At the postsynaptic density (PSD), …

Soluble oligomers of the amyloid-β (Aβ) peptide are thought to play a key role in the
pathophysiology of Alzheimer's disease (AD). Recently, we reported that synthetic Aβ oligomers …

Epileptic activity is frequently associated with Alzheimer's disease; this association has
therapeutic implications, because epileptic activity can occur at early disease stages and might …

Delineating the molecular basis of synapse development is crucial for understanding brain
function. Cocultures of neurons with transfected fibroblasts have demonstrated the synapse-…

Objective Currently no effective disease‐modifying agents exist for the treatment of Alzheimer
disease (AD). The Fyn tyrosine kinase is implicated in AD pathology triggered by amyloid‐…

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, afflicting more than
one-third of people over the age of 85. While many therapies for AD are in late-stage clinical …

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder. Early
in the pathophysiology of AD, synaptic function is disrupted by soluble Aβ oligomers, …